Table 3. Adipose-derived MSCs therapy clinical trials for multiple sclerosis disease.

Cell type	Years	Country	Phase	Evaluation after cell therapy	NCT number (clinicaltrials.gov)
Autologous ADMSCs	2018 (12)	Spain	1 & 2	Infusion of autologous ADMSCs is safe and feasible in patients with SPMS	NCT01056471
Autologous ADMSCs	2012–2015	Sweden	1 & 2	Safety of IV therapy with autologous MSCs in MS patients. incidence of relapses and disability progression	NCT01730547
Autologous ADMSCs	2014–2018	German	1	Modified SF-36 for Cell-Based Therapy Follow Up, Multiple Sclerosis Impact Scale (MSIS-29), incidence and nature of adverse events, serious adverse events, or any unanticipated adverse events	NCT02326935
Autologous ASVFs	2014–2018	USA	2	Change from baseline in sexual satisfaction at month 12 as measured by participants using the SSS. Bowel control at month 12 as measured by participants using the BWCS. Social support as measured by participants using the MSSS	NCT02157064

MSCs, mesenchymal stem cells; ADMSCs, adipose-derived mesenchymal stem cells; ASVF, adipose stromal vascular fraction; IV, intravenous; MS, multiple sclerosis; SSS, Sexual Satisfaction Scale; BWCS, Bowel Control Scale; MSSS, Modified Medical Outcomes Study Social Support Survey; SF-36, Short Form 36.